Last reviewed · How we verify
Aspirin loading dose
Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes to reduce thromboxane A2 production and platelet aggregation.
Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes to reduce thromboxane A2 production and platelet aggregation. Used for Acute coronary syndrome (ACS) and myocardial infarction, Stroke prevention in patients with prior ischemic stroke or transient ischemic attack, Stable coronary artery disease.
At a glance
| Generic name | Aspirin loading dose |
|---|---|
| Also known as | Acetylsalicylic acid, ASA |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Drug class | Antiplatelet agent; nonsteroidal anti-inflammatory drug (NSAID) |
| Target | Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Aspirin acetylates serine residues on COX-1 and COX-2 enzymes, permanently blocking their catalytic activity. This prevents the synthesis of thromboxane A2 in platelets, a potent platelet activator and vasoconstrictor, thereby reducing platelet aggregation and thrombotic events. A loading dose delivers a rapid, high concentration to achieve quick antiplatelet effects, particularly important in acute coronary syndromes.
Approved indications
- Acute coronary syndrome (ACS) and myocardial infarction
- Stroke prevention in patients with prior ischemic stroke or transient ischemic attack
- Stable coronary artery disease
- Primary prevention of cardiovascular events (select populations)
Common side effects
- Gastrointestinal bleeding
- Dyspepsia
- Nausea
- Hemorrhagic stroke
- Allergic reaction / Anaphylaxis
Key clinical trials
- Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia (PHASE4)
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (PHASE3)
- Efficacy and Safety of Tirofiban for Patients With BAD (BRANT) (PHASE3)
- A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects (PHASE1)
- ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion (PHASE4)
- Aspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion (PHASE4)
- Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention (PHASE4)
- Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aspirin loading dose CI brief — competitive landscape report
- Aspirin loading dose updates RSS · CI watch RSS
- Icahn School of Medicine at Mount Sinai portfolio CI